These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18347106)

  • 21. Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors.
    Ma H; Leveque V; De Witte A; Li W; Hendricks T; Clausen SM; Cammack N; Klumpp K
    Virology; 2005 Feb; 332(1):8-15. PubMed ID: 15661135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of 3'-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymerase.
    Shim JH; Larson G; Wu JZ; Hong Z
    J Virol; 2002 Jul; 76(14):7030-9. PubMed ID: 12072503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.
    Dhanak D; Duffy KJ; Johnston VK; Lin-Goerke J; Darcy M; Shaw AN; Gu B; Silverman C; Gates AT; Nonnemacher MR; Earnshaw DL; Casper DJ; Kaura A; Baker A; Greenwood C; Gutshall LL; Maley D; DelVecchio A; Macarron R; Hofmann GA; Alnoah Z; Cheng HY; Chan G; Khandekar S; Keenan RM; Sarisky RT
    J Biol Chem; 2002 Oct; 277(41):38322-7. PubMed ID: 12167642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.
    Harper S; Pacini B; Avolio S; Di Filippo M; Migliaccio G; Laufer R; De Francesco R; Rowley M; Narjes F
    J Med Chem; 2005 Mar; 48(5):1314-7. PubMed ID: 15743173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase.
    Zhong W; Uss AS; Ferrari E; Lau JY; Hong Z
    J Virol; 2000 Feb; 74(4):2017-22. PubMed ID: 10644375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Template requirement and initiation site selection by hepatitis C virus polymerase on a minimal viral RNA template.
    Oh JW; Sheu GT; Lai MM
    J Biol Chem; 2000 Jun; 275(23):17710-7. PubMed ID: 10749880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isolation and characterization of RNA aptamers specific for the HCV minus-IRES domain I.
    Konno K; Fujita S; Iizuka M; Nishikawa S; Hasegawa T; Fukuda K
    Nucleic Acids Symp Ser (Oxf); 2008; (52):493-4. PubMed ID: 18776469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro Selection of High Affinity DNA and RNA Aptamers that Detect Hepatitis C Virus Core Protein of Genotypes 1 to 4 and Inhibit Virus Production in Cell Culture.
    Torres-Vázquez B; de Lucas AM; García-Crespo C; García-Martín JA; Fragoso A; Fernández-Algar M; Perales C; Domingo E; Moreno M; Briones C
    J Mol Biol; 2022 Apr; 434(7):167501. PubMed ID: 35183559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of HCV RNA-dependent RNA polymerase activity by aqueous extract from Fructus Ligustri Lucidi.
    Kong L; Li S; Han X; Xiang Z; Fang X; Li B; Wang W; Zhong H; Gao J; Ye L
    Virus Res; 2007 Sep; 128(1-2):9-17. PubMed ID: 17531344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus.
    Luo G; Hamatake RK; Mathis DM; Racela J; Rigat KL; Lemm J; Colonno RJ
    J Virol; 2000 Jan; 74(2):851-63. PubMed ID: 10623748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
    Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral therapy: inhibition of Hepatitis C Virus expression by RNA interference directed against the NS5B region of the viral genome.
    Trejo-Avila L; Elizondo-González R; Trujillo-Murillo Kdel C; Zapata-Benavides P; Rodríguez-Padilla C; Rivas-Estilla AM
    Ann Hepatol; 2007; 6(3):174-80. PubMed ID: 17786145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of constrained peptides that bind to and preferentially inhibit the activity of the hepatitis C viral RNA-dependent RNA polymerase.
    Amin A; Zaccardi J; Mullen S; Olland S; Orlowski M; Feld B; Labonte P; Mak P
    Virology; 2003 Aug; 313(1):158-69. PubMed ID: 12951030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Site-specific cleavage of HCV genomic RNA and its cloned core and NS5B genes by DNAzyme.
    Kumar D; Chaudhury I; Kar P; Das RH
    J Gastroenterol Hepatol; 2009 May; 24(5):872-8. PubMed ID: 19220662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An oligonucleotide complementary to the SL-B1 domain in the 3'-end of the minus-strand RNA of the hepatitis C virus inhibits in vitro initiation of RNA synthesis by the viral polymerase.
    Reigadas S; Ventura M; Andreola ML; Michel J; Gryaznov S; Tarrago-Litvak L; Litvak S; Astier-Gin T
    Virology; 2003 Sep; 314(1):206-20. PubMed ID: 14517074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.
    Umehara T; Fukuda K; Nishikawa F; Sekiya S; Kohara M; Hasegawa T; Nishikawa S
    Nucleic Acids Symp Ser (Oxf); 2004; (48):195-6. PubMed ID: 17150545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
    Young KC; Lindsay KL; Lee KJ; Liu WC; He JW; Milstein SL; Lai MM
    Hepatology; 2003 Oct; 38(4):869-78. PubMed ID: 14512874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage.
    Devogelaere B; Berke JM; Vijgen L; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Nyanguile O; Tahri A; Amssoms K; Lenz O; Cummings MD; Clayton RF; Vendeville S; Raboisson P; Simmen KA; Fanning GC; Lin TI
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4676-84. PubMed ID: 22710121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of inhibition for BMS-791325, a novel non-nucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Rigat KL; Lu H; Wang YK; Argyrou A; Fanslau C; Beno B; Wang Y; Marcinkeviciene J; Ding M; Gentles RG; Gao M; Abell LM; Roberts SB
    J Biol Chem; 2014 Nov; 289(48):33456-68. PubMed ID: 25301950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.